Danish-founded biotech company Pila Pharma looks to secure a partnership

The Danish-founded biotech company Pila Pharma said Wednesday in a press release it looks to secure a partnership or acquisition within the next few years. The short-term goal is to advance the development of a promising new drug candidate for the treatment of obesity and diabetes.

Pila Pharma, listed on the Nasdaq First North stock exchange in Stockholm, has set a clear strategy for the future: Within a few years, the company aims to be acquired by or partner with an industry player capable of furthering and realizing its research in obesity and other metabolic diseases using TRPV1 inhibitors. The goal is to ensure that Pila Pharma’s potential new weight-loss pill reaches the market as quickly as possible.

– We have a promising drug candidate with a completely different side effect profile compared to other treatments currently in development or on the market. Our ambition is to progress the candidate over the next few years and then hand it over to a larger player who can take it to the next level. The global market is in dire need of effective obesity treatments, particularly scalable pill-based solutions, and we believe we could have a role to play in this development, says CEO Gustav H. Gram, adding:

– Since our founders’ discovery in 1999 and the company’s founding in 2014, we have made significant progress and gathered data that suggests we are on the right track. The next major step is to establish proof of concept for weight loss. We are the only company working with this specific type of molecule—TRPV1 inhibitors—as a novel therapeutic approach to treating obesity and other metabolic diseases. If we succeed, I firmly believe we will emerge as a strong and attractive candidate for partnership or acquisition.